• AAPL 186.28
  • TSLA 171.89
  • AMZN 186.57
  • MSFT 413.72
  • INTC 30.51
  • EURUSD 1.0791
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. WAR /
  3. CTX.WAR

Captor Therapeutics S.A. (CTX WAR) stock market data APIs

zł76.2 -0.8(-1%) as of May 13, 2024

Captor Therapeutics S.A. Financial Data Overview

77
76.2
-
79
75.2
59-165
355 M
4 646 K
12 537 K
-2.4724
0.59
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'CTX',
Type: 'Common Stock',
Name: 'Captor Therapeutics S.A.',
Exchange: 'WAR',
CurrencyCode: 'PLN',
CurrencyName: 'Polish złoty',
CurrencySymbol: 'zł',
CountryName: 'Poland',
CountryISO: 'PL',
OpenFigi: NULL,
ISIN: 'PLCPTRT00014',
CIK: NULL,
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: NULL,
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
}

Captor Therapeutics S.A. Fundamental Data is available in our Financial Data APIs

  • Net Revenue 12 537 K
  • EBITDA -63 728 000
  • Earnings Per Share -15.2
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Captor Therapeutics S.A. Earnings via APIs

  • Latest Release 2024-04-09
  • EPS/Forecast NaN

Get Captor Therapeutics S.A. End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Captor Therapeutics S.A. latest news via APIs

Captor Therapeutics Publishes Q1 2023 Financial Results

Lead asset CT-01 on track for clinical trial application authorization in Q3 2023 Collaboration with Ono Pharmaceuticals in neurological diseases progressing according to planSolid cash position allow...
  • CAPTOR THERAPEUTICS
  • EARNINGS RELEASES AND OPERATING RESULTS
  • WARSAW STOCK EXCHANGE:CTX

Captor Therapeutics Discloses Molecular Targets of Pipeline’s Lead Assets and Invites Stakeholders to Webcast

CT-01 targets 3 well suited proteins including NEK7 with poor prognosis in key liver cancer Strong preclinical data generated with CT-02 against NEK7CT-05 potential best-in-class profile in high poten...
  • CAPTOR THERAPEUTICS
  • CONFERENCE CALLS/ WEBCASTS
  • WARSAW STOCK EXCHANGE:CTX
Do you have any questions?
support@eodhistoricaldata.com